Journal · Updated 2026-08-11
Tirzepatide for Sleep Apnea: The FDA-Approved Indication Most People Don't Know Exists
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Zepbound carries a second FDA indication almost nobody shops on: moderate-to-severe obstructive sleep apnea in adults with obesity, approved in December 2024 on the SURMOUNT-OSA trials, where tirzepatide reduced the apnea-hypopnea index by roughly twenty-five to thirty events per hour against about five with placebo, with a substantial share of participants reaching remission-range severity — with and without concurrent CPAP. Two practical consequences follow. Clinically: for the large population where obesity drives the apnea, treating the weight now has a first-line pharmacologic option with its own trial program. Financially: an OSA diagnosis is a second door to insurance coverage — plans that carve out "weight-loss drugs" may still cover Zepbound for its sleep-apnea indication, which can turn a four-forty-nine cash decision into a twenty-five-dollar copay.
What the trials showed, read carefully
SURMOUNT-OSA ran as two parallel studies — participants not on CPAP, and participants staying on it — and the headline held in both: large AHI reductions on tirzepatide, modest ones on placebo, alongside the expected weight loss and improvements in oxygen-desaturation and cardiovascular-risk markers. The mechanism is unglamorous and strong: excess tissue around the airway is a principal driver of obstruction, and a twenty-percent body-weight reduction physically changes the airway's mechanics — which is also the honest caveat: the indication is for OSA with obesity, and apnea driven primarily by craniofacial anatomy or other causes isn't the studied population. CPAP remains the standard it was; the trials position tirzepatide as treatment for the underlying driver, not a mask replacement on night one — many patients run both, then retest.
Using the indication, practically
Three moves. If you have diagnosed moderate-to-severe OSA and obesity, raise the indication with the prescribing conversation explicitly — it changes the risk-benefit ledger and the documentation. If your insurance excludes weight-management drugs, have the prior authorization filed under the OSA indication with the sleep-study documentation attached; carve-outs are indication-specific more often than plans advertise, and this is among the highest-yield coverage arguments in the class. And if you're on CPAP: the endpoint that matters is a repeat sleep study after meaningful weight loss, ordered by the clinician managing the apnea — self-discontinuing the mask because the scale moved is the error the trials' design specifically didn't test. Compounded tirzepatide, for completeness, carries no indication for anything — the OSA evidence and the coverage door belong to the approved product.
Questions people ask
Is tirzepatide FDA-approved for sleep apnea?
Yes — Zepbound was approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, on the SURMOUNT-OSA trials (AHI reductions of roughly 25–30 events/hour vs ~5 on placebo, with and without CPAP). The indication belongs to the approved product, not compounded versions.
Can sleep apnea get Zepbound covered by insurance?
Often — it's a second coverage door: plans that exclude 'weight-loss drugs' may cover the OSA indication. File the prior authorization under sleep apnea with the sleep-study documentation attached; a covered outcome can mean a $25 copay instead of $449 cash.
Can I stop CPAP if I start tirzepatide?
Not on your own: the trials studied tirzepatide with and without CPAP, and the correct endpoint is a repeat sleep study after meaningful weight loss, ordered by your sleep clinician. Many patients run both until the retest says otherwise.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.